0

Purchase Short-Term Access

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents: A Cost-Effectiveness Analysis
Axel Finckh, MD, MS; Nick Bansback, MS; Carlo A. Marra, PharmD, PhD; Aslam H. Anis, PhD; Kaleb Michaud, PhD; Stanley Lubin, MD; Marc White, PhD; Sonia Sizto, BA; Matthew H. Liang, MD, MPH
Annals of Internal Medicine 2009;151:612-621. doi:10.7326/0003-4819-151-9-200911030-00006

Purchase Online access to this article for 24 hours
Buy Now

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)